41
Participants
Start Date
March 31, 2023
Primary Completion Date
March 31, 2025
Study Completion Date
September 1, 2025
Pirfenidone
200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
RECRUITING
Hubei Cancer Hospital, Wuhan
Hubei Cancer Hospital
OTHER